10X Genomics Inc

TXGNASDAQ NMS - GLOBAL MARKET

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for 10X Genomics Inc.